Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., & Rutter, W. J. (1979) · Biochemistry · doi:10.1021/bi00591a005 · Cited by 21,725
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“The p53 protein is a tumor suppressor gene product that can block progression of cells through the cell cycle and/or induce apoptosis (Sionov and Haupt, 1999; Somasundaram and El-Deiry, 2000; Vogelstein et al., 2000).”
BackgroundA novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985 · cited 1×
“Transcriptional activation is mediated by p53 binding to a consensus sequence consisting of two copies of a decamer motif 5'-RRRCWWGYYY-3' separated by 0 to 13 bp of random sequence (El-Deiry et al., 1992).”
BackgroundControl of apoptosis and mitotic spindle checkpoint by survivin
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., & Altieri, D. C. (1998) · Nature · doi:10.1038/25141 · Cited by 1,870
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., & Murphy, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106643200 · Cited by 794
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.
Kawasaki, H., Altieri, D. C., Lu, C., Toyoda, M., Tenjo, T., & Tanigawa, N. (1998) · PubMed · Cited by 706
An Anti-apoptotic Protein Human Survivin Is a Direct Inhibitor of Caspase-3 and -7
Shin, S., Sung, B.-J., Cho, Y.-S., Kim, H.-J., Ha, N.-C., Hwang, J.-I., Chung, C.-W., Jung, Y.-K., & Oh, B.-H. (2001) · Biochemistry · doi:10.1021/bi001603q · Cited by 674
Takahashi, Y., Rayman, J. B., & Dynlacht, B. D. (2000) · Genes & Development · doi:10.1101/gad.14.7.804 · Cited by 621
Research works printed but not linked: 3
- Santoso JT, Tang D-C, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci III JA, Miller DS, Mathis JM . 1995 Gynecol. Oncol. 59: 171–178 · doi:10.1006/gyno.1995.0002
- Somasundaram K, El-Deiry WS . 2000 Frontiers in Bioscience 5: 424–437 · doi:10.2741/a523
- Wen SF, Xie L, McDonald M, DiGiacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B, Nielsen LL . 2000 Cancer Gene Ther. 7: 1469–1479 · doi:10.1038/sj.cgt.7700257
Cited by
Validating survivin as a cancer therapeutic target
Altieri, D. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc968 · Cited by 1,206
Decision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,068
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Survivin, versatile modulation of cell division and apoptosis in cancer
Altieri, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207113 · Cited by 900
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0746 · Cited by 765
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 606
Transcriptional Regulation by P53
Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569
Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465
Survivin: A new target for anti-cancer therapy
Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 379
Sugiura, R., Satoh, R., & Takasaki, T. (2021) · Cells · doi:10.3390/cells10102509 · Cited by 369
Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Structural, functional and therapeutic biology of survivin
Sah, N. K., Khan, Z., Khan, G. J., & Bisen, P. S. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.03.007 · Cited by 355
Survivin: A molecular biomarker in cancer
Mittal, R., Jaiswal, P., & Goel, A. (2015) · Indian Journal of Medical Research · doi:10.4103/0971-5916.159250 · Cited by 352
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
Chen, X., Duan, N., Zhang, C., & Zhang, W. (2016) · Journal of Cancer · doi:10.7150/jca.13332 · Cited by 347
p53-Dependent Transcriptional Repression of c-myc Is Required for G1 Cell Cycle Arrest
Ho, J. S. L., Ma, W., Mao, D. Y. L., & Benchimol, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7423-7431.2005 · Cited by 312
Survivin study: What is the next wave?
Li, F. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10327 · Cited by 309
Rödel, F., Hoffmann, J., Distel, L., Herrmann, M., Noisternig, T., Papadopoulos, T., Sauer, R., & Rödel, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3028 · Cited by 292
Which cell death modality wins the contest for photodynamic therapy of cancer?
Mishchenko, T., Balalaeva, I., Gorokhova, A., Vedunova, M., & Krysko, D. V. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04851-4 · Cited by 276
Zaffaroni, N., Pennati, M., Colella, G., Perego, P., Supino, R., Gatti, L., Pilotti, S., Zunino, F., & Daidone, M. G. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8518-3 · Cited by 275
The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer
NACHMIAS, B., ASHHAB, Y., & BENYEHUDA, D. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.002 · Cited by 266
Inhibition of pluripotent stem cell-derived teratoma formation by small molecules
Lee, M.-O., Moon, S. H., Jeong, H.-C., Yi, J.-Y., Lee, T.-H., Shim, S. H., Rhee, Y.-H., Lee, S.-H., Oh, S.-J., Lee, M.-Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303669110 · Cited by 246
p21/CDKN1A Mediates Negative Regulation of Transcription by p53
Löhr, K., Möritz, C., Contente, A., & Dobbelstein, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212517200 · Cited by 227
p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2.
Aliouat-Denis, C.-M., Dendouga, N., Van den Wyngaert, I., Goehlmann, H., Steller, U., van de Weyer, I., Van Slycken, N., Andries, L., Kass, S., Luyten, W., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0121 · Cited by 177
Zaky, A., Busso, C., Izumi, T., Chattopadhyay, R., Bassiouny, A., Mitra, S., & Bhakat, K. K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1173 · Cited by 111
Watching the watcher: Regulation of p53 by mitochondria
Holley, A. K., & St Clair, D. K. (2009) · Future Oncology · doi:10.2217/14796694.5.1.117 · Cited by 75
Bhowmick, R., & Girotti, A. W. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.12.005 · Cited by 67
“Its expression in carcinoma cells is also known to be enhanced by low levels of endogenous or exogenous NO [49] and to be repressed by p53 [50].”
BackgroundRossi, M., Demidov, O. N., Anderson, C. W., Appella, E., & Mazur, S. J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn888 · Cited by 57
p53-mediated heterochromatin reorganization regulates its cell fate decisions.
Mungamuri, S. K., Benson, E. K., Wang, S., Gu, W., Lee, S. W., & Aaronson, S. A. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2271 · Cited by 53
Zhu, N., Gu, L., Li, F., & Zhou, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0179 · Cited by 42
Lenos, K., de Lange, J., Teunisse, A. F., Lodder, K., Verlaan-de Vries, M., Wiercinska, E., van der Burg, M. J., Szuhai, K., & Jochemsen, A. G. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-111 · Cited by 16
Metadata
- Authors
- Mirza, A., McGuirk, M., Hockenberry, T. N., Wu, Q., Ashar, H., Black, S., Wen, S. F., Wang, L., Kirschmeier, P., Bishop, W. R., Nielsen, L. L., Pickett, C. B., & Liu, S.
- Venue
- Oncogene
- Published
- 2002-04-18
- Volume
- 21
- Issue
- 17
- Pages
- 2613-2622
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1992960292
- Cited by
- 530
- References
- 37
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.